Suchergebnisse - "Kazandjian, Dickran"

PubPharm (95)

11

Extreme body mass index and survival in newly diagnosed multiple myeloma patients

enthalten in: Blood cancer journal | 2023

von Shah, U. | Whiting, K. | Devlin, S. | +16

12

T cell redirecting bispecific antibodies for multiple myeloma : emerging therapeutic strategies in a changing treatment landscape

enthalten in: Leukemia & lymphoma | 2022

von Kazandjian, D. | Kowalski, A. | Landgren, O.

13

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

enthalten in: bioRxiv.org | 2022

von Yang, Y. | Oellerich, T. | Chen, P. | +23

14

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

enthalten in: NPJ precision oncology | 2022

von Nguyen, N. | Chaudhry, S. | Totiger, T. | +16

15

Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma : pooled analysis of four single-arm studies

enthalten in: Leukemia & lymphoma | 2022

von Landgren, O. | Kazandjian, D. | Roussel, M. | +7

16

Publisher Correction : Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

enthalten in: Nature communications | 2022

von Yang, Y. | Bolomsky, A. | Oellerich, T. | +23

ErratumFor: Nat Commun. 2022 Sep 17;13(1):5469. - PMID 36115844

17

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

enthalten in: Nature communications | 2022

von Yang, Y. | Bolomsky, A. | Oellerich, T. | +23

ErratumIn: Nat Commun. 2022 Oct 3;13(1):5830. - PMID 36192480

18

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Landgren, O. | Kazandjian, D.

CommentOn: J Clin Oncol. 2022 Sep 1;40(25):2889-2900. - PMID 35377708

19

Novel Quadruplets and the Age of Immunotherapies in the Treatment of Newly Diagnosed Multiple Myeloma

enthalten in: JAMA oncology | 2022

von Kazandjian, D. | Landgren, O.

CommentOn: JAMA Oncol. 2022 Sep 1;8(9):1278-1286. - PMID 35862034

20

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies

enthalten in: JCO global oncology | 2022

von Fatoki, R. | Koehn, K. | Kelkar, A. | +8